Tarsus Pharmaceuticals TARS
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Tarsus Pharmaceuticals (TARS) Business Model and Operations Summary
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.
Key Insights
Tarsus Pharmaceuticals (TARS) Core Market Data and Business Metrics
Latest Closing Price
$48.92Market Cap
$2.04 BillionPrice-Earnings Ratio
-15.93Total Outstanding Shares
41.61 Million SharesTotal Employees
323Dividend
No dividendIPO Date
October 16, 2020SIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
15440 Laguna Canyon Road, Irvine, CA, 92618
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Investing Activities, Continuing | $-199.19 Million |
| Net Cash Flow From Investing Activities | $-199.19 Million |
| Net Cash Flow From Operating Activities, Continuing | $-83.03 Million |
| Net Cash Flow | $-127.57 Million |
| Net Cash Flow, Continuing | $-127.57 Million |
| Net Cash Flow From Operating Activities | $-83.03 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Income/Loss From Continuing Operations After Tax | $-115.55 Million |
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Income/Loss From Continuing Operations Before Tax | $-115.55 Million |
| Nonoperating Income/Loss | $5.01 Million |
| Income Tax Expense/Benefit, Deferred | $0 |
| Basic Average Shares | $37.60 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $-115.37 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $181,000 |
| Comprehensive Income/Loss | $-115.37 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Wages | $15.82 Million |
| Other Current Assets | $339.44 Million |
| Current Assets | $356.70 Million |
| Current Liabilities | $80.61 Million |
| Liabilities And Equity | $376.99 Million |
| Liabilities | $152.46 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||